About Neornat

History

04
Selected for the 'Startup Leap Package' hosted by the Ministry of SMEs and Startups
01
Entered into a financial advisory agreement with InDeal Co., Ltd.

12
Transfer of in vitro diagnostic medical device technology from CUK-IACF
09
Celebrated the 5th anniversary of NEORNAT Co., Ltd.
07
Signed an MOU with MediRama Inc. for drug development and clinical collaboration
06
Signed a joint R&D agreement with Certest for RNA-based lung cancer gene therapy, NRT-YHD_002
Application for Prior review of NRT-YHD_001 to the Ministry of Food and Drug Safety (MFDS)
05
Selected for the 2025 Startup-Focused University (Prospective) Startup Project
01
Signed an MOU with Beyond Bridge & Co. for technology transfer and investment attraction

06
Selected for the 'POST-TIPS Program' hosted by the Ministry of SMEs and Startups
05
CEO Seok-Woo Nam delivered a special presentation at BioKorea 2024 on next-generation drug platform development strategies
04
Selected for the KDDF Global Technology Transfer and Co-development Program

12
Entered into an agreement with Liberi Group for global technology transfer and multinational joint development
Secured KRW 1.5 billion investment from Korea Technology Finance Corporation (KIBO)
07
Signed a joint R&D agreement with CellArtgen Co., Ltd. for RNA-based liver cancer gene therapy
04
Selected for the Korea Drug Development Fund (KDDF) program (nonclinical stage)
Completed IND-enabling package for macrophage-activating RNA immunotherapy for liver cancer, NRT-YHD_001
02
Signed a business agreement for IND approval of RNA-based anti-cancer drug NRT-YHD_001 with AIMSBiosciences Co., Ltd.

09
Established NEORNAT Corporate R&D Center
06
Selected as a Top 5 finalist and chosen as a best company at SteinTech Bio Season 1
03
Secured KRW 2.7 billion in Pre-Series A investment
02
Signed an MOU with LabGenomics Co., Ltd. for research and development of RNA-based anticancer therapeutics

12
Executed a license-out agreement with KPS Co., Ltd. for liver cancer diagnostic biomarkers
Transfer of anticancer drug development technology from CUK-IACF
11
Entered into an agreement with Algok Bio Inc. regarding the status of preferred bidder for the RT-LET7 liver cancer therapeutic
06
Selected for the 'TIPS Program' hosted by the Ministry of SMEs and Startups
01
Changed company name to NEORNAT Co., Ltd.